Glancy Prongay & Murray LLP (“GPM”) reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the “Class Period”). Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Esperion's business and prospects to shareholders, including that there was no clear path to approval for ETC-1002, that the FDA had encouraged Esperion to initiate a cardiovascular outcomes trial ("CVOT") and that completion of a CVOT could be necessary prior to approval of ETC-1002. Upon disclosure that the Company would need to perform additional CVOTs prior to approval, shares of Esperion fell dramatically, over $16 per share, or nearly 50%, to close on September 29, 2015 at $18.33 per share.

If you purchased shares of Esperion during the Class Period you may move the Court no later than March 14, 2016 to request appointment as lead plaintiff. If you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy, 310-201-9150 or 888-773-9224shareholders@glancylaw.comwww.glancylaw.com

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Esperion Therapeutics Charts.
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Esperion Therapeutics Charts.